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Abstract 
 Heart health is important for the overall normal function of the body. Given the 
complexity of all heart diseases, especially when each person’s experience is different, there 
are various options to help a patient become healthier. This MQP examines the effectiveness of 
several cardiac solutions to determine the best solutions for patients. Our primary focus is on 
the evolution of stents and a comparison of the commonly used stents to other surgical 
options.  
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Introduction 
Our primary focus is on the issues surrounding the health of the heart. With each 
medical issue, there are certain paths that a patient can take. We want to make sure patients 
are more aware of the potential surgical options and the issues that are associated with each 
route. Surgical solutions can be very costly depending on the severity of the disease, insurance 
coverage, doctor preference, and which option will be the most beneficial to the patient. Some 
options may have similar results and patients may undergo procedures that are unnecessary 
and overly costly when compared to other solutions.  
The specific heart diseases that may result in the placement of stents or other 
procedures such as angioplasty, minimally invasive surgery and open heart surgery include 
coronary heart disease, angina, and myocardial infarctions (heart attack), which are all 
interrelated.  Coronary heart disease occurs when the heart, the body’s pump, is damaged with 
resultant insufficient oxygen to the rest of the body. If this disease is severe enough, it could 
result in a myocardial infarction, but if less severe there may be strong signs of angina. For each 
of these heart diseases medications, stenting, angioplasty, and some kind of heart surgery can 
be used for treatment. Each of the treatments has its own costs, benefits, procedure time, 
recovery time, and long term and short term results.  
The final result of our paper resulted in a comprehensive look at the heart itself, and 
some of the causes of heart malfunction mentioned. In order to clearly discuss the different 
types of surgical solutions for these heart diseases, we learned the evolution of heart surgery 
and the newer medical procedures, such as stents, that are available for patient use. We not 
only discussed stents that surround the heart, but how stents could be used in other areas of 
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the body. From there, we evaluated the pros and cons of stent use and the role that stents play 
in the surgical arena. Also discussed are the different surgical solutions besides stents that can 
be used. The possible future role of stents, including biodegradable stents, was also examined. 
After evaluating the uses and roles of stents, it was possible to evaluate comparative costs of 
each procedure and how one choice can impact future medical and financial decisions of the 
patient. 
From our comprehensive comparison analysis, we were able to evaluate what type of 
procedure might be best for the patient and present our finding in a clear format.  
Problem Statement 
The heart is an organ that is vital for survival. The body requires oxygen to function 
properly, and the heart provides the mechanism to supply oxygen throughout the body. When 
doctors first began attempting to surgically intervene when the heart malfunctioned, the 
recovery process that followed was long and expensive. As surgical practices have evolved, the 
monetary cost of heart surgery has declined, as have the risks that patients have faced while 
undergoing such a procedure. However, it is imperative that research into advancing practices 
is continued in the hope that costs and health risks continue to fall. Money, time and long term 
results all need to be considered as a whole in order to assess the measures that need to be 
taken in order to make the best decision for each individual patient.  
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Methods 
The goal of our project is to effectively raise patient awareness about not only surgical 
procedures but the costs associated with each procedure. In order to collect the most 
appropriate data, the tasks performed included the following: 
1. Literature Review 
2. Interviews 
The literature review included extensive research on patents of the various types of stents, 
reviewing of scholarly articles and research about the costs of stents and the other types of 
procedures for cardiac diseases. The topics listed above are further elaborated on in the 
Discussion portion of this paper.  
 The interview conducted was with a professor from Worcester Polytechnic Institute, 
Satya Shivkumar. The notes from the interview are found in Appendix B. This personal interview 
proved to be very effective in obtaining the essential information for our project and in 
analyzing the problem.  
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Results 
The four main options for different heart issues and disease were found to be 
medication, stents, minimally invasive surgery, and open heart surgery. Stents are thoroughly 
discussed because of the flexibility of the procedure. It involves a form of angioplasty, the use 
of medication, and small scale surgery to implant the stent in the precise location. The use of 
stents encompasses a number of components of other options to help with the heart issue.  
The other surgical options discussed have higher percentages of risk for various matters 
than stents. Open heart surgery and minimally invasive surgery involve different sizes of 
incision in a variety of locations which may pose a threat to the body in terms of recovery. 
Stents also involve some risk with clot formation around the stent or the need for a new stent. 
All the options must be discussed and considered in order to assess the correct options for a 
patient depending on the complexity of their heart issue.  
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Discussion 
The Heart  
The heart is the pump of the body. A normal functioning heart distributes oxygen to all 
the tissues, maintains levels of nutrients and wastes, regulates body temperature, distributes 
body heat, and protects against blood loss through clotting. There are two networks or circuits 
of vessels and capillaries that transport blood to and from the lungs (pulmonary circuit) and 
deliver blood to the body and back to the heart (systemic circuit). The four chambers of the 
heart assist the two circuits. The right atrium receives blood, low in oxygen and rich in carbon 
dioxide, from the superior and inferior vena cava. From the right atrium, blood is pumped into 
the right ventricle then to the lungs. These two chambers service the pulmonary circuit. The left 
atrium receives re-oxygenated blood via the pulmonary veins. The left atrium and left ventricle 
pump blood into the aorta which supplies oxygen to all tissues and organs and picks up the 
cellular waste of carbon dioxide. The left atrium and left ventricle are part of the systemic 
circuit. (Figure 1)  
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Figure 1: Anatomy of the Heart1 
Blood flows through a series of veins, arteries and capillaries, from the heart via arteries 
to the capillaries and back to the heart via veins. Arteries include the aorta, ones that are 
embedded to the heart muscle wall providing oxygen to the cardiac cells, and muscular arteries 
that give a person their pulse. Capillaries facilitate the exchange of nutrients and waste which 
form a branching network on all body tissues.  
Mechanism of Action of Platelets 
Platelets usually have a disc shape but when activated, they change into a compact 
sphere with cilia-like extensions that aid in adhesion. The localization and adhesion of platelets 
allows for the body to be protected from blood loss. The platelets secrete adenosine 
diphosphate (ADP), calcium and different proteins which allow for the surface membrane of 
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platelets to become ‘sticky’ and form a clot. This localization forms a clot to allow for proper 
healing of an affected area.  
Such clotting is not ideal when a person is dealing with different heart problems such as 
plaque buildup, recent heart attack, narrowing of capillaries, etc. When a patient currently has 
some sort of heart problem, one of the common options for a first step is for a patient to take 
some type aspirin or Plavix. Aspirin is usually administered in order to thin the blood, enabling 
the blood to flow more easily and reducing the risk of a future clot. Plavix removes the 
stickiness from the platelets in order to keep from forming clots. These drugs can be taken in 
conjunction to stent placement, allowing for a lower risk of a blood clot forming on a stent, 
leading to further heart attacks and possibly death.2  
Reasons for Intervention 
 Before a heart attack, coronary heart disease or angina occurs, there are preceding 
heart issues that can aid in the severity of a disease. A few of those include stenosis, high blood 
pressure, plaque buildup, and high cholesterol. Stenosis is the narrowing of the arterial walls 
whereas high blood pressure is associated with the hardening of arterial walls. Both of these 
can make it harder for the heart to pump the blood effectively. Plaque buildup is usually caused 
by high cholesterol and years of cholesterol buildup on the artery walls will create a blockage in 
the artery.3 
 Stenosis, high blood pressure, high cholesterol, and especially plaque buildup restrict 
the blood flow to the heart or to the rest of the body. Dizziness, shortness of breath, chest pain, 
fatigue, headaches may be caused by the lack of blood flow throughout the body. If any of the 
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conditions listed were to worsen, coronary heart disease or angina could be developed. This 
would cause persistent chest pain and the potential for additional heart issues. If a plaque 
buildup were to rupture, blood flow would drastically be reduced initiating heart muscle death 
and probable myocardial infarction. 
 The goals for each of these issues or diseases differ depending on the severity therefore 
requiring a specific solution or form of intervention.  It may vary from changing life style habits 
for health to taking aspirin or Plavix to stenting or some kind of surgical procedure. Each of 
these options has a set of long term and short term goals in order to prevent a future incident 
and help a patient live longer.  
Drug Design  
 Aspirins and Plavix are anticoagulants. Coagulation occurs with platelets and proteins, 
which platelets secrete upon activation. The two anticoagulants mentioned inhibit the clotting 
ability of platelets by making platelets ‘less sticky’ and increasing the clotting time.  The 
antiplatelet agent or the anticoagulation of platelets in aspirin and Plavix is used because it 
decreases the risk of clotting in affected areas. The risks can include thrombosis, myocardial 
infarction, coronary heart disease, plaque buildup, and a stroke.4  
 Though the involvement of the drugs has proved to be beneficial to those that suffer 
from some kind of heart problem, it can still involve some risk. A longer clotting time can cause 
for patients to bruise more easily. This blood loss can be prolonged after operations or just a 
nick on the leg. Even with the costs, in most scenarios, the anticoagulation of the blood is 
beneficial to an older patient or one with a heart condition.   
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Design of Stents 
Stents are designed in such a way that they are collapsible, yet retain their tensile 
strength when deployed. As such, many bare metal stents are constructed using an alloy called 
Nitanol, which is a nickel-titanium alloy. This alloy allows for superior flexibility as well as 
allowing for a smaller profile when compared to titanium counterparts. Currently, there are 
two main stent designs, open cell and closed cell. (Figures 2 and 3) These have little difference 
in most mechanical functions, yet there appears to be a difference in the healing factors caused 
by the dissimilarities in cell design. In one study, there were no statistically significant 
differences in health factors caused by cell design, yet there was a numerical difference in 
outcomes. What occurred can be seen in Figure 3. Numerically, closed cell stents are safer for 
the patient than open cell stents, however the numerical differences did not translate into any 
statistically significant outcomes.5 
 
Figure 2: Open versus Closed Cell Stents 
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Figure 3: Health differences between stent designs 
6
 
 
Reasons for a Stent 
Restenosis is the recurrence of stenosis, the abnormal narrowing in a blood vessel or 
other tubular structure. Restenosis in this case refers to the narrowing of a vessel following 
treatment. To date, no surgery has proven one hundred percent effective in preventing 
restenosis, although advances in technology have allowed for restenosis rates to decrease. In 
balloon angioplasty, the restenosis rate usually falls around forty percent, while traditional 
stents drop that rate to around twenty five percent.  
13 
 
When a bare metal stent is placed in the body, tissue begins to envelop the stent and 
covers the struts of the stent. This process is called endothelization and is necessary for the 
healing of arterial walls. In the early stages of healing, the tissue growing is healthy cell wall 
tissue from the arterial wall of the blood vessel. Later, scar tissue could form underneath the 
new tissue. If this layer of tissue is too thick, it could obstruct normal blood flow, and cause 
similar health complications as the original problem.  (Figure 4) 
 
Figure 4: Implementation of a Stent 7 
 
One of the other issues with stents is incomplete endothelization of the stent struts, 
which can lead to stent thrombosis. Incomplete endothelization is when the arterial wall cells 
do not completely cover the stent struts. (Figure 5) The body reacts to the foreign body inside 
the vessel, and both platelets and white blood cells converge on the struts. The platelets begin 
to form a clot, which could eventually detach from the vessel wall and cause either a 
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myocardial infarction or a stroke. Late stent thrombosis (LST), which occurs later than one 
month following surgery, is a large problem in patients who receive a drug-eluting stent. In bare 
metal stents, complete endothelization is usually evident at around 28 days, whereas drug-
eluting stents uniformly showed incomplete healing at 180 days, in one study. Late stent 
thrombosis has been documented in both clinical and autopsy studies in patients as far as four 
years after stent insertion. Late stent thrombosis was found to be most associated with a 
discontinuation of proper drug treatment or hypersensitivity to the polymer found in drug-
eluting stents.  
 
 
Figure 5: Restenosis of a stent 8 
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Evolution of Stents 
Bare Metal Stents 
In 1977, a process called Percutaneous Transluminal Coronary Angioplasty (PTCA) was 
developed. This process is a minimally invasive surgery that is intended to open blocked veins 
and arteries within the body by utilizing a balloon catheter. The catheter is inflated at the site of 
the blocked artery, flattening plaque buildup and allowing for normal function to continue. 
Several years later, in 1986, a coronary stent was developed to hold open vessels and to 
attempt to lower restenosis rates in patients, which were around 30-40% of patients 
undergoing PTCA. Restenosis is clinically evident within the first 6-9 months after stent 
placement, and occurs in response to injury and inflammation due to the foreign body in the 
blood stream. Therefore, when implanting stents into the body became a normal procedure, 
restenosis rates became a concern for both patients and doctors.  
In addition to restenosis, PTCA and stent implantation can cause exaggerated 
endothelial injury and inflammation, rendering both the stent and vessel highly thrombogenic. 
A fibrinogen layer covers the stent surface, further inducing platelet activation and thrombosis. 
Combining anti-platelet medication with stenting procedures is crucial in preventing local 
coronary thrombosis, myocardial infarction and death. Current recommendations for patients 
with bare-metal stents include dual anti-platelet therapy with aspirin and clopidogrel, which are 
continued for 6 weeks to allow complete endothelialization of stents. The incidence of 
myocardial infarction and death were significantly lower among patients who underwent 
surgery after their 6-week course of aspirin and clopidogrel were completed.8 
16 
 
Drug-Eluting Stents 
In 2001, drug-eluting stents were introduced as a strategy to minimize restenosis and 
requirement for surgical re-intervention. The currently available polymer-coated stents contain 
antiproliferative agents which elute locally in the implanted coronary artery to prevent 
restenosis. (Figure 6) Initial animal studies demonstrated a clear benefit over bare metal stents 
(4-6% restenosis versus 20-30%), and early clinical trials further supported this. At present, 90% 
of all stents placed in the United States and Europe are drug eluting. 
Despite the enthusiasm that resulted with the advent of drug eluting stents, incomplete 
endothelialization and stent thrombosis continue to plague these devices. Initial animal studies 
demonstrated complete endothelialization with BMS at 28 days, whereas drug eluting stents 
uniformly showed incomplete healing at 180 days. Based on early observations in both animal 
and human studies, it was recommended that patients with drug eluting stents receive dual 
anti-platelet therapy with aspirin and clopidogrel for at least 3-12 months, followed by life-long 
aspirin therapy, depending on the stent placed and the pre-existing co-morbidities which 
further increase the risk of stent thrombosis. Despite this regimen, late stent thrombosis 
remains a significant complication in patients with drug eluting stents. Late stent thrombosis 
carries a 45% mortality rate, usually through myocardial infarction or sudden death. Late stent 
thrombosis has been documented in both clinical and autopsy studies in patients as far as four 
years after stent insertion.8 
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Figure 6: Bare metal versus drug eluting stents 8 
 
Biodegradable Stents 
Bioabsorbable and biodegradable stents are designed in a similar way to traditional 
metal stents. The stent is helical in shape, with an inner core and exterior surface. The rates of 
degradation of the inner and outer cores are typically calibrated in such a way that the inner 
core degrades first, and the outer core will provide structure and support for a set period of 
time before degrading. The inner core can be made from a monomer from one of the following 
groups: lactide, glycolide, paradioxanone, caprolactone, and trimethylene carbonate, 
caprolactoe and blends and copolymers of these groups. The outer layer consists of a co-
polymer of lactide and glycolide of varying consistencies. The inner core typically degrades by 
hydrolysis into smaller pieces that are filtered by the body, while the outer core degrades into a 
fibrillar morphological structure.9 
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Although an improvement, biodegradable stents have some limitations. The overall 
strength and durability of the stents, when compared to traditional bare metal stents, is 
significantly lower. This causes the stents to need thicker support structures, limiting their 
usefulness in smaller vessels. The absorption rate can be so slow, that it leads restenosis. Since 
many are non-metallic, it is harder to see the stents while placing them within the body, and 
can lead to incorrect placement and force re-intervention.10 
Expanded Uses 
Stents are designed to hold open any passageway in the body that, for one reason or 
another, has closed or partially closed. Although primarily used in cardiac treatment, stents 
have been utilized in the legs, urinary tract, and esophagus.  Recently, researchers at Brown 
Medical School in Providence, R.I., have reported that stent placement should be considered 
the standard of care for treating patients with abnormal circulation, or "ischemia" to the legs, 
due to obstruction of the iliac arteries. The iliac arteries are large arteries in the pelvis that 
supply blood to the legs.  
Lower-extremity ischemia, a type of peripheral vascular disease, occurs when arteries in 
the abdomen or pelvis, called the aorta and iliac arteries, respectively, narrow or become 
completely blocked by the build-up of atherosclerotic plaque deposits. As a result, not enough 
oxygen-rich blood gets to the legs, causing cramps and pain and making it difficult to walk or 
exercise. Rarely, the condition becomes so severe that gangrene develops or amputation of the 
affected limb is necessary. Until the introduction of the stent 10 years ago, the only way to 
open up such vessels was surgically, bypassing the blockage with a healthy vein or artery.  
Increasingly, interventional radiologists are treating the condition with a less invasive stenting 
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procedure, in which a catheter-or thin, flexible tube-is inserted through a small incision in the 
skin and threaded to the site of the blocked artery. The vessel is pumped open by a tiny 
balloon, and the stent is inserted to hold open the blood vessel.11  
Minimally Invasive Surgery  
 Minimally invasive surgery has advanced drastically in the medical field, providing a 
procedure that is less hazardous to patients. Four criteria make minimally invasive surgery 
significantly different than open heart surgery, including faster recovery period, smaller 
incisions, less damage to surrounding tissue, and most of the time no cardiopulmonary bypass 
machine. This procedure cannot be done for every heart disease because it is dependent on the 
location of the problem on the heart but it is usually done on the front of the heart and on 
coronary arteries.  
 There are many variations to minimally invasive surgery. This is so because the smaller 
incisions can be performed in many locations around the chest such as part of the breast bone, 
between the ribs, and underneath the sternum. (Figure 7) The flexibility of this procedure 
allows for more areas of the heart to be targeted. Typically, more than one incision is made so 
that tools can be used effectively by the surgeon. There have also been developments of robot-
assisted surgery where the surgeon controls robotic arms holding the tools during the surgery.  
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Figure 7: Incision Areas for Minimally Invasive Surgery12 
The robotic arm approach allows for a less invasive surgery. The incisions made allow for 
only tools to go into the body with a robotic extension that surgeons can manipulate. This 
allows for surgeons to become more effective and capable for perform the surgery. Having the 
robotic aspect, the surgery involves even smaller incisions, more precision, and quicker healing 
times.13  
Risks and Benefits  
 The surgery, like any, has several risks involved. There may be some complications 
especially since the heart, most of the time, is still beating. The heart is still beating so that the 
risks involved with blood reentering the blood pathways and heart is non-existent. There will 
also be pain at the site of the incisions, which should not exceed more than 2-3 inches. Since 
the surgery is at the heart, there could still be risk of blood clots, blood loss, heart attack, 
strokes or infections.14  
The surgery is usually performed if there are one or two blockages typically in front of 
the heart. This type of surgery is very specialized because it takes a steady hand in order to 
perform the surgery effectively. The surgery can be complex and risky in the sense of 
performing the surgery through a small hole and a surgeon must have control or use the 
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robotic arm. This is especially important because the surgeon and the robotic arm must be able 
to navigate to the correct location of the blockage without damaging other tissues.  
Minimally invasive surgery has less of a risk than open heart surgery even though at 
most times the heart is beating. The surgery results in less hospital time, saving money. The 
residual soreness will not be as great because there will be smaller incisions than for open heart 
surgery. Therefore, there is a lesser risk of clotting.   
Open Heart Surgery  
 Traditional heart surgery involves making an incision that cuts through the length of the 
entire breast bone and requires a heart-lung machine. The heart is stopped and the blood is 
drained from the area. The heart-lung machine acts as a pump for the blood to flow through 
the body and helps the lung perform normally. After the operation has been completed, the 
surgeon allows flow of the blood to the heart in order to revive the heart and body. This type of 
surgery usually involves some type of grafting to the capillaries or arteries of the heart from 
another part of the body and can last upwards to 4 hours or more.14  
Risks and Benefits  
 As mentioned above for any type of surgery, there are certain risks. With draining the 
heart of blood, there is risk of complications such as clotting as the blood is flowing back into 
the heart. Also, there is a risk of a stroke and potentially memory problems. Breaking the entire 
sternum can cause some problems as well. Opening the chest has quite a bit of recovery time 
since the whole bone is split. There is especially more risk for infection through an open heart 
surgery because the size of the incision. There will definitely be chest pain present as well as a 
longer stay in the hospital and recovery time that can range from a few weeks to a few 
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months.15 Figure 8 compares the different incisions between a traditional open heart surgery 
and those made in a robotic minimally invasive surgery (MIS).  
 
Figure 8: Open Heart Surgery incision (left) compared to incisions made with robotic MIS16 
 The heart-lung machine provides support for the heart and the lungs during the surgery. 
There is not blood flowing through the heart until it flows back through. Though the heart does 
need the blood and oxygen to pump, the length of time the heart is without it could cause 
some lung failure or heart rhythm problems.  
Patient Perspective 
Some religious beliefs conflict with current medical practices. Parents who are set in 
their beliefs can sometimes prevent treatment for both themselves and their children. There 
have been many cases over the years of parents being charged with the deaths of their children 
by refusing to take them to the doctor. Two of the largest dominations that are in favor of 
prayer over treatment are the Church of Christ and Jehovah’s Witnesses.  
The Church of Christ promotes healing of physical and mental illnesses through prayer. 
Recently they have begun to compromise when dealing with broken bones, allowing members 
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to have their bones set by a doctor and then returning to prayer. However, many Christian 
Scientists object to medicine and doctors as a whole, for both themselves and their children. 
The majority of their beliefs are based on the New Testament, where Jesus was documented as 
healing the sick through prayer.17 
Jehovah’s Witnesses are a religious group that has interpreted several passages of the 
Bible to mean that they must refuse blood transfusions, even in the face of death. According to 
Jehovah’s Witnesses, any member that willingly accepts a blood transfusion is committing a sin. 
In the case of a simple medical procedure, such as a stent implementation, this might not be an 
issue. However, for more invasive open heart surgery, blood transfusions are necessary.18  
Comparison of Treatments 
For patients with stenosis 
 50% undergo angioplasty  
 20% undergo a stenting procedure 
o 90% of those stents are drug eluting 
 Every patient is put on some kind of medication 
o Medicines used to treat CHD include anticoagulants, aspirin and other 
anticlotting medicines; ACE inhibitors; beta blockers; calcium channel blockers; 
nitroglycerin; glycoprotein IIb-IIIa; statins; and fish oil and other supplements 
high in omega-3 fatty acids. 
 Risk  
o Angioplasty has less than 1% chance of death19  
 Requires about a day or less of hospitalization after procedure  
 Catheter can cause bleeding or damage blood vessels; dye used  could 
cause allergic reaction -> kidney problems20  
o Likeliness of restenosis – 20-30% 
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o Emergency bypass surgery is around - 2% 
o Stent risk 
 Blood clots can form around the stent (1-2% of patients) 
 The highest in the first few months of the stent being placed 
 Risk is reduced by anti-clotting drugs and anti-coagulants. 
 Likeliness of restenosis after stent is about 20 % on average 
 4-5% for  drug eluting stents and around 40% for bare metal 
stents that properly heal 
o Minimally invasive surgery21 
 Requires less time in hospital than open heart surgery.  
 There is a greater learning curve for surgeons to perform minimally 
invasive surgery over open heart surgery 
 The small incisions don’t leave much room for movement so 
preciseness is necessary  
 Open heart surgery22  
o Risks- stroke, heart attack, graft failure, death (3 out of 100 procedures), 
bleeding  
 Grafting23 
o Saphenous vein graft vs internal-mammary-artery graft to the anterior 
descending coronary artery alone or combined with one or more saphenous-vein 
grafts 
o patients who had only vein grafts had a 1.6 times greater risk of death 
throughout the 10 years, as compared with those who received an internal-
mammary-artery graft. 
o In addition, patients who received only vein grafts had 1.41 times the risk of late 
myocardial infarction, 1.25 times the risk of hospitalization for cardiac events 
2.00 times the risk of cardiac reoperation, and 1.27 times the risk of all late 
cardiac events, as compared with patients who received internal-mammary-
artery grafts.23 
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The Future of Intervention 
Initially, when a patient requires intervention to hopefully prevent future heart 
conditions, the mechanical support that a stent provides allows for more complete healing of 
the arterial walls. However, beyond the first few months the mechanical support is no longer 
required. However, if a stent is placed properly and proper healing takes place, it is virtually 
impossible to remove that stent. The scientific community has begun to take an interest in bio-
absorbable stents, due to their potential in reducing common risk factors of traditional stents. 
One of the main arguments in favor of developing a bio-absorbable stent is due to the 
progression of restenosis, which can be found even seven to ten years after a stent has been 
implemented due to lack of endothelization. There have been several successful trials in 
humans of bio-absorbable stents; however none are currently available for commercial use. 
The stents that are currently in trials have a wide range of both mechanical properties as well as 
materials that go into the stent make-up. Theoretically, this type of stent could dramatically 
alter the way that doctors approach medical procedures. These stents would allow for repeated 
re-intervention and potentially less long-term health complications for the patient.24 
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Conclusion and Recommendations 
Currently, a bare metal stent with a closed cell structure is the most beneficial answer to 
stenosis for the patient. Bare metal stents have a more consistent healing time than drug 
eluting stents, which allow for more accurate predictions of both restenosis and thrombosis. 
The chemical make-up of drug eluting stents does not provide the patient with an overall safer 
healing process due to the problems that are most commonly associated with stents, namely 
late stent thrombosis. Studies have shown that bare metal stents have a higher endothelization 
rate than other stents, meaning that they are a safer statistical option than other stents on the 
market. Additionally, if incomplete endothelization does occur, the mechanical properties of 
bare metal stents, namely the metallic structure, allow doctors to view the stent without 
surgery and predict potential complications in the stent, helping to alleviate patient concerns 
about unpredictable late stent thrombosis.  
 A stent is not a magic solution for every cardiac issue. They are most effective when 
paired with the appropriate drugs that prevent the body’s natural defense mechanisms from 
inadvertently causing the patient harm. Without proper monitoring by doctors, patients will 
return to the hospital with the same complications as before, or even potentially worse health 
issues. Stenting is a preventative measure that should be used with caution in order to provide 
the most benefit to the greatest number of patients.   
In the future, hopefully, medical technology will have progressed for enough to allow for 
bio-absorbable stents becoming a reality for all patients. Scientists should strive to create a 
material that allows for a smooth transition for doctors. This material could be used to create a 
stent that remains in the body for long enough to provide the initial mechanical support 
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necessary, but will slowly be absorbed by the body and either eliminated as waste or utilized in 
some other function. This type of stent would eliminate life-long drug therapy, reducing long-
term side effects on the patient body.  
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Appendices  
Appendix A- Proposal 
Original Proposal 
As the life-span of humans continues to grow, doctors are being forced to deal with more 
patients with more complex medical issues. Many patients are not aware of all of the surgical 
paths that they can take, and as a result patient care can decline. Our primary focus is on the 
issues surrounding the health of the heart and the lack of general knowledge about the heart. 
Patients need to become more aware of the potential surgical options and the issues that are 
associated with each route. Surgical solutions can be very costly, and patients can be duped 
into undergoing procedures that are unnecessary and overly costly when compared to other 
solutions.  
In order to most effectively raise patient awareness about not only surgical procedures but 
the costs associated with each procedure, we will perform a literature review of scholarly 
articles as well as patents for stents. We will also conduct interviews of both professors familiar 
with stents, and doctors in the cardiac field.  
The final result of our paper will be a comprehensive look at the heart itself, and some of 
the causes of heart malfunction that result in medical complications. In order to clearly discuss 
the different types of surgical solutions, we will discuss the evolution of heart surgery and the 
newer medical procedures, such as stents, that are available for patient use. We will discuss not 
only stents that surround the heart, but how stents could be used in other areas of the body. 
From there, we can evaluate the pros and cons of stent use and the role that stents play in the 
surgical arena. Also discussed, will be the different surgical solutions that can be paired with 
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stents. The possible future role of stents, including biodegradable stents will be examined, 
along with a look into the future of cardiac surgery. After evaluating the uses and roles of 
stents, it will be possible to evaluate comparative costs or each procedure and how one choice 
can impact future medical and financial decisions of the patient. 
From our comprehensive comparison analysis, we will be able to accurately evaluate what 
type of procedure is best for the patient and present our finding in a clear and succinct format. 
The patient can use our report to assist in the decision making process before choosing a 
surgical path.  
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Appendix B- Interview 
Professor Satya Shivkumar Interview Notes 
 Drug eluding stents peaked in 2007 
o Market value was at 5 billion and is now at 2.5 billion 
o Now in decline because of problems that arose 
 Was supposed to minimize restenosis but actually accelerated it 
 Narrowing of the blood vessel leading to restricted blood flow  
 Stents require a medication for blood thinning.  
 Drug encased in a polymer coating on a stent 
o Drug effects surface properties of the metal (polarity, etc.): therefor it was less 
effective than bare metal stents 
o Process to put the drug onto the metal affected the patency rate 
 Likelihood that the vessel will stay open  
o The drug, paclitaxel, was not the problem; it was the encasing changing 
properties.  
 Surgeons are reluctant to change and about 70-80% of stents used in surgery are 
actually stainless steel/metal stents 
 The release of drugs to the blood stream is through gradual diffusion over time.  
o Initial release is a decent amount and then the rate gradually goes down 
 The drug used, paclitaxel, is also a drug used in cancer treatments 
o It blocks the blood supply to the cancer cell to prevent internal layers of the wall 
 Minimizes inflammation  
o Good short term but not so good long term 
 Depends on the person  
 Stents are usually a permanent fix and it should not be done repeatedly  
 People still are doing research into drug eluting stents but the research is progressively 
slowing down due to poor results 
o Drugs may be different. Dependent on the mechanic properties of the tissues 
and stents  
 Biodegradable stents 
o Not as supportive as the metal stent which is a good thing to the tissue 
surrounding the stent 
 The support may make the rest of the capillary weaker, therefore the 
possibility of more stents increases 
o The stent is in for the length of time it is needed and then will no longer be a 
potential hazard  
 Variable to the amount of time it is necessary a person needs it  
